Emerging treatments in neurogastroenterology: A multidisciplinary working group consensus statement on opioid-induced constipation

Neurogastroenterology and Motility

Volumn 26, Issue 10, 2014, Pages 1386-1395

  Camilleri, M ^a   Drossman, D A ^b   Becker, G ^c   Webster, L R ^d   Davies, A N ^e   Mawe, G M ^f  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

^d PRA HEALTH SCIENCES   (United States)

^e ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^f UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Opioid induced constipation; Pain; Palliative care; Quality of life; opioid receptor

Indexed keywords

NARCOTIC ANALGESIC AGENT; OPIATE RECEPTOR;

CHEMICALLY INDUCED; COMPLICATION; CONSENSUS DEVELOPMENT; CONSTIPATION; DRUG EFFECTS; GASTROINTESTINAL DISEASE; HUMAN; INTESTINE INNERVATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANALGESICS, OPIOID; CONSTIPATION; ENTERIC NERVOUS SYSTEM; GASTROINTESTINAL DISEASES; HUMANS; RECEPTORS, OPIOID;

EID: 84908209365     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12417     Document Type: Review

References (61)

1. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid complications and side effects. Pain Physician 2008; 11: S105-20.
2. Hewitt K, Lin H, Faraklas I, Morris S, Cochran A, Saffle J. Use of methylnaltrexone to induce laxation in acutely injured patients with burns and necrotizing soft-tissue infections. J Burn Care Res 2014; 35: e106-11.
3. Gonenne J, Camilleri M, Ferber I, Burton D, Baxter K, Keyashian K, Foss J, Wallin B et al. Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol 2005; 3: 784-91.
4. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10: 113-30.
5. Jamison RN, Edwards RR. Risk factor assessment for problematic use of opioids for chronic pain. Clin Neuropsychol 2013; 27: 60-80.
6. Warner EA. Opioids for the treatment of chronic noncancer pain. Am J Med 2012; 125: 1155-61.
7. Argoff CE, Silvershein DI. A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clin Proc 2009; 84: 602-12.
8. Fine PG, Mahajan G, McPherson ML. Long-acting opioids and short-acting opioids: appropriate use in chronic pain management. Pain Med 2009; 10(Suppl. 2): S79-88.
9. Grunkemeier DM, Cassara JE, Dalton CB, Drossman DA. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol 2007; 5: 1126-39; quiz 1-2.
10. Luo M, Li L, Lu CZ, Cao WK. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2011; 23: 1250-7.
11. Tuteja AK, Biskupiak J, Stoddard GJ, Lipman AG. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil 2010; 22: 424-30, e96.
12. Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician 2006; 74: 1347-54.
13. Thompson JR. Treatment guidelines for hepatic encephalopathy. Pharmacotherapy 2010; 30: 4S-9S.
14. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001; 182: 11S-8S.
15. Kraichely RE, Arora AS, Murray JA. Opiate-induced oesophageal dysmotility. Aliment Pharmacol Ther 2010; 31: 601-6.
16. Alame AM, Bahna H. Evaluation of constipation. Clin Colon Rectal Surg 2012; 25: 5-11.
17. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004; 112: 372-80.
18. Sykes NP. The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med 1998; 12: 375-82.
19. Cook SF, Lanza L, Zhou X, Sweeney CT, Goss D, Hollis K, Mangel AW, Fehnel SE. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther 2008; 27: 1224-32.
20. Tassinari D, Sartori S, Tamburini E, Scarpi E, Raffaeli W, Tombesi P, Maltoni M. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med 2008; 11: 492-501.
21. Hjalte F, Berggren AC, Bergendahl H, Hjortsberg C. The direct and indirect costs of opioid-induced constipation. J Pain Symptom Manage 2010; 40: 696-703.
22. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med 2009; 10: 35-42.
23. Holzer P, Ahmedzai SH, Niederle N, Leyendecker P, Hopp M, Bosse B, Spohr I, Reimer K. Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. J Opioid Manag 2009; 5: 145-51.
24. Chamberlain BH, Cross K, Winston JL, Thomas J, Wang W, Su C, Israel RJ. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. J Pain Symptom Manage 2009; 38: 683-90.
25. Sloots CE, Rykx A, Cools M, Kerstens R, De Pauw M. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci 2010; 55: 2912-21.
26. Gaertner J, Siemens W, Camilleri M, Davies A, Drossman DA, Webster L, Becker G. Definitions, assessment tools and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. J Clin Gastroenterol 2014; In press.
27. Choung RS, Locke GR 3rd, Schleck CD, Zinsmeister AR, Talley NJ. Cumulative incidence of chronic constipation: a population-based study 1988-2003. Aliment Pharmacol Ther 2007; 26: 1521-8.
28. Webster L, Dhar S, Eldon M, Masuoka L, Lappalainen J, Sostek M. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain 2013; 154: 1542-50.
29. Clark K, Currow DC. Constipation in palliative care: what do we use as definitions and outcome measures? J Pain Symptom Manage 2013; 45: 753-62.
30. Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol 2011; 106: 835-42.
31. Kaufman PN, Krevsky B, Malmud LS, Maurer AH, Somers MB, Siegel JA, Fisher RS. Role of opiate receptors in the regulation of colonic transit. Gastroenterology 1988; 94: 1351-6.
32. Maurer AH, Krevsky B, Knight LC, Brown K. Opioid and opioid-like drug effects on whole-gut transit measured by scintigraphy. J Nucl Med 1996; 37: 818-22.
33. Heaton KW, Radvan J, Cripps H, Mountford RA, Braddon FE, Hughes AO. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut 1992; 33: 818-24.
34. Phongsamran PV, Kim JW, Cupo Abbott J, Rosenblatt A. Pharmacotherapy for hepatic encephalopathy. Drugs 2010; 70: 1131-48.
35. Nullens S, Nelsen T, Camilleri M, Burton D, Eckert D, Iturrino J, Vazquez-Roque M, Zinsmeister AR. Regional colon transit in patients with dys-synergic defaecation or slow transit in patients with constipation. Gut 2012; 61: 1132-9.
36. Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007; 61: 1181-7.
37. Thomas JR, Cooney GA, Slatkin NE. Palliative care and pain: new strategies for managing opioid bowel dysfunction. J Palliat Med 2008; 11: S1-19; quiz S21-2.
38. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De Conno F et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012; 13: e58-68.
39. Smith B. Effect of irritant purgatives on the myenteric plexus in man and the mouse. Gut 1968; 9: 139-43.
40. Milner P, Belai A, Tomlinson A, Hoyle CH, Sarner S, Burnstock G. Effects of long-term laxative treatment on neuropeptides in rat mesenteric vessels and caecum. J Pharm Pharmacol 1992; 44: 777-9.
41. ® (lubiprostone capsules). Full Prescribing Information. Bethesda, MD: Sucampo Pharma Americas, LLC, and Deerfield, IL: Takeda Pharmaceuticals America, Inc., 2013.
42. Mazen Jamal M, Mareya SM, Woldegeorgis F, Joswick TR, Ueno Joswick R. Lubiprostone significantly improves treatment response in non-methadone opioid-induced bowel dysfunction patients with chronic, non-cancer pain: results from a phase 3, randomized, double-blind, placebo-controlled clinical trial. Gastroenterology 2012; 142: S144-5.
43. Stein C, Clark JD, Oh U, Vasko MR, Wilcox GL, Overland AC, Vanderah TW, Spencer RH. Peripheral mechanisms of pain and analgesia. Brain Res Rev 2009; 60: 90-113.
44. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002; 23: 48-53.
45. Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 1996; 10: 135-44.
46. ® (methylnaltrexone bromide subcutaneous injection). Full Prescribing Information. Raleigh, NC: Salix Pharmaceuticals, Inc., 2012.
47. ® (alvimopan). Full Prescribing Information. Lexington, MA: Cubist Pharmaceuticals, Inc., 2012.
48. Kraft MD. Emerging pharmacologic options for treating postoperative ileus. Am J Health Syst Pharm 2007; 64: S13-20.
49. Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ 3rd. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991; 101: 927-34.
50. Cuppoletti J, Chakrabarti J, Tewari K, Malinowska DH. Methadone but not morphine inhibits lubiprostone-stimulated Cl- currents in T84 intestinal cells and recombinant human ClC-2, but not CFTR Cl- currents. Cell Biochem Biophys 2013; 66: 53-63.
51. Merkel IS, Locher J, Burgio K, Towers A, Wald A. Physiologic and psychologic characteristics of an elderly population with chronic constipation. Am J Gastroenterol 1993; 88: 1854-9.
52. Skollerud LM, Fredheim OM, Svendsen K, Skurtveit S, Borchgrevink PC. Laxative prescriptions to cancer outpatients receiving opioids: a study from the Norwegian prescription database. Support Care Cancer 2013; 21: 67-73.
53. Webster L, Jansen JP, Peppin J, Lasko B, Irving G, Morlion B, Snidow J, Pierce A et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 2008; 137: 428-40.
54. Larkin PJ, Sykes NP, Centeno C, Ellershaw JE, Elsner F, Eugene B, Gootjes JR, Nabal M et al. The management of constipation in palliative care: clinical practice recommendations. Palliat Med 2008; 22: 796-807.
55. Ishihara M, Ikesue H, Matsunaga H, Suemaru K, Kitaichi K, Suetsugu K, Oishi R, Sendo T et al. A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin J Pain 2012; 28: 373-81.
56. National Comprehensive Care Network (NCCN). Clinical Practice Guidelines in Oncology v.2. 2013. Available at: http://www.nccn.org/professionals/physician_gls/pdf/pain.pdf.
57. Ross GR, Gabra BH, Dewey WL, Akbarali HI. Morphine tolerance in the mouse ileum and colon. J Pharmacol Exp Ther 2008; 327: 561-72.
58. Rosti G, Gatti A, Costantini A, Sabato AF, Zucco F. Opioid-related bowel dysfunction: prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatment. Eur Rev Med Pharmacol Sci 2010; 14: 1045-50.
59. Rentz AM, Yu R, Muller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 2009; 12: 371-83.
60. Camilleri M, Rothman M, Ho KF, Etropolski M. Validation of a bowel function diary for assessing opioid-induced constipation. Am J Gastroenterol 2011; 106: 497-506.
61. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. Available at: www.cochrane-handbook.org.